Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

被引：29

作者：

Bendell, Johanna C.

LoRusso, Patricia

Overman, Michael J.

Noonan, Anne M.

Kim, Dong-Wan

Strickler, John

Kim, Sang-We

Clarke, Stephen John

George, Thomas J.

Grimison, Peter S.

Barve, Minal A.

Amin, Manik A.

Desai, Jayesh

Wise-Draper, Trisha

Cooper, Zachary

Elgeioushi, Nairouz

Mueller, Nancy Kathryn

Kumar, Rakesh

Wu, Kevin YuFeng

Patel, Sandip Pravin

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[2] Yale Univ, Canc Ctr, New Haven, CT USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Duke Univ, Med Ctr, Durham, NC USA

[7] Asan Med Ctr, Seoul, South Korea

[8] Royal North Shore Hosp, St Leonards, NSW, Australia

[9] Univ Florida, UF Hlth Canc Ctr, Gainesville, FL USA

[10] Chris OBrien Lifehouse, Sydney, NSW, Australia

[11] Mary Crowley Canc Res Ctr, Dallas, TX USA

[12] Washington Univ, Sch Med, St Louis, MO USA

[13] Royal Melbourne Hosp, Parkville, Vic, Australia

[14] Univ Cincinnati, Med Ctr, Cincinnati, OH USA

[15] Astrazeneca, Gaithersburg, MD USA

[16] Moores Canc Ctr, La Jolla, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9047

引用

页数：2